Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Minerva reported Q2 2026 financials showing GAAP net income of $17.5 million, driven entirely by a $27.6 million non-cash gain on warrant liability changes, while the underlying adjusted net loss widened to $7.8 million due to increased Phase 3 trial costs. Operationally, the confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia is on track, with topline efficacy data expected in the second half of 2027, and the company expanded its Scientific Advisory Board with three new experts.
Key figures
- Eps
- 0.36
- Cash position
- $75.4 million
- Ga expense q2
- $3.5 million
- Rd expense q2
- $7.2 million
- Adjusted net loss q2
- $7.8 million
- Warrant liability gain q2
- $27.6 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.